Eikonizo Therapeutics Overview

  • Founded
  • 2017
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series A
  • (Cancelled)
  • Latest Deal Amount
  • $22.5M
Latest Deal Amount
  • Investors
  • 4

Eikonizo Therapeutics General Information

Description

Producer of small molecule therapeutic drugs designed to offer amyloid-positive and mild-to moderate-cognitive impairment remedies. The company's drugs use PET imaging in the drug discovery process to de-risk novel targets and lead therapeutic candidates, enabling researchers to envision an accelerated path to drug discovery and development.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Lab Central
  • 700 Main Street North
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eikonizo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 11-Apr-2020 $22.5M Cancelled Pre-Clinical Trials
2. Accelerator/Incubator 000 Completed Pre-Clinical Trials
1. Seed Round 16-May-2018 $2M $2M 000 Completed Startup
To view Eikonizo Therapeutics’s complete valuation and funding history, request access »

Eikonizo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00.00 00 00 00 00 000
To view Eikonizo Therapeutics’s complete cap table history, request access »

Eikonizo Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Janice Kranz Ph.D Co-Founder, Chief Executive Officer & Board Member
Frederick Schroeder Ph.D Co-Founder & Director of Research & Development
William Shaw JD Co-Founder & Board Member
Jacob Hooker Ph.D Co-Founder
Richard Margolin MD Chief Medical Officer
To view Eikonizo Therapeutics’s complete executive team members history, request access »

Eikonizo Therapeutics Board Members (4)

Name Representing Role Since
Janice Kranz Ph.D Eikonizo Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
Kevin Kinsella Self Board Member 000 0000
Stacie Weninger Ph.D Self Board Member 000 0000
William Shaw JD Eikonizo Therapeutics Co-Founder & Board Member 000 0000
To view Eikonizo Therapeutics’s complete board members history, request access »

Eikonizo Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eikonizo Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
Kevin Kinsella Angel (individual) Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
To view Eikonizo Therapeutics’s complete investors history, request access »